Therapeutic directions for Parkinson's disease

Movement Disorders

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Shoulson, Ira ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Experimental therapeutics; Parkinson's disease; Uric acid

Indexed keywords

BIOLOGICAL MARKER; CEP 1347; PLACEBO; URIC ACID;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE COURSE; GENOTYPE; HUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; FACTUAL DATABASE; METHODOLOGY; STATISTICS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 77953373922     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22790     Document Type: Article

References (15)

1. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007; 69: 1480-1490.
2. Olanow CW, Schapira AH, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006; 5: 1013-1020.
3. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006; 72: 1197-1206.
4. Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007; 114: 261-277.
5. Shoulson I. Experimental neurotherapeutics: leaps and bounds. Archiv Neurol 2002; 59: 689-691.
6. Maroney AC, Finn JP, Connors TJ, et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001; 276: 25302-25308.
7. Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 2004; 62: 330-332.
8. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
9. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Archiv Neurol 2008; 65: 716-723.
10. Ascherio A, LeWitt P, Watts A, et al.; on behalf of the PSG DATATOP Investigators. CSF as well as serum urate are predictors of Parkinson's disease progression. Late-breaking abstract of the Movement Disorder Society's Tenth International Congress of Parkinson's Disease and Movement Disorders, Kyoto, Japan, October 30 to November 2, 2006.
11. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007; 166: 561-567.
12. Zerhouni EA. Translational and clinical science-time for a new vision. New Eng J Med 2005; 353: 1621-1623.
13. Parkinson Study Group, Tanner CM presenter. Follow-up of persons with neurologic diseases (FOUND): up to 46 months follow-up. Mov Disord 2006; 21 ( Suppl 13): S127.
14. Shoulson I; Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann Neurol 1998; 44(3 Suppl 1 ): S160-S166.
15. Shoulson I, Oakes D, Fahn S, et al. Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 2002; 51: 604-612.